{
    "clinical_study": {
        "@rank": "144586", 
        "arm_group": [
            {
                "arm_group_label": "HCP1104", 
                "arm_group_type": "Experimental", 
                "description": "HCP1104"
            }, 
            {
                "arm_group_label": "Mulex Tab. and  Airtal Tab.", 
                "arm_group_type": "Active Comparator", 
                "description": "Eperisone Hydrochloride and Aceclofenac"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate pharmacokinetics and safety after oral\n      administration of HCP1104 and Eperisone Hydrochloride plus Aceclofenac."
        }, 
        "brief_title": "Partial Replicated Crossover Clinical Study to Compare Pharmacokinectic Characteristics of Eperisone Hydrochloride and Aceclofenac With HCP1104 Treatment to Those of Co-administration of Eperisone Hydrochloride 50mg Tablet and Aceclofenac 100mg Tablet in Healthy Adult Male Volunteers", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "The purpose of this study is to evaluate pharmacokinetics and safety after oral\n      administration of HCP1104 and Eperisone Hydrochloride plus Aceclofenac."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male volunteers, age between 20 and 45\n\n          -  BMI of \uff1e20kg/m2 and \uff1c28kg/m2 subject\n\n          -  Informed of the investigational nature of this study and voluntarily agree to\n             participate in this study\n\n        Exclusion Criteria:\n\n          -  Use of any prescription medication within 14 days prior to Day 1\n\n          -  Use of any medication within 7 days prior to Day 1\n\n          -  Participation in another clinical study within 60 days prior to start of study drug\n             administration"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01869985", 
            "org_study_id": "HM-EPAC-102"
        }, 
        "intervention": {
            "arm_group_label": [
                "HCP1104", 
                "Mulex Tab. and  Airtal Tab."
            ], 
            "description": "HCP1104 / Eperisone plus Aceclofenac", 
            "intervention_name": "HCP1104 / Mulex Tab. and Airtal Tab.", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Eperisone", 
                "Aceclofenac", 
                "Diclofenac"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "HCP1104", 
            "Eperisone Hydrochloride", 
            "Aceclofenac"
        ], 
        "lastchanged_date": "March 8, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Asan Medical Center"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Open-label, Single Dose, 3-sequence and 3-period Partial Replicated Crossover Clinical Study to Compare Pharmacokinectic Characteristics of Eperisone Hydrochloride and Aceclofenac With HCP1104 Treatment to Those of Co-administration of Eperisone Hydrochloride 50mg Tablet and Aceclofenac 100mg Tablet in Healthy Adult Male Volunteers", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Area Under Curve(AUC) last", 
            "safety_issue": "Yes", 
            "time_frame": "0, 20, 40min, 1, 1.5, 2,  3, 4, 6, 8, 10, 12, 24h  hours post-dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01869985"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Hanmi Pharmaceutical Company Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hanmi Pharmaceutical Company Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}